Xeris Biopharma Holdings, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Xeris Biopharma Holdings, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2020 to Q3 2024.
  • Xeris Biopharma Holdings, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $6.77M, a 175% increase year-over-year.
  • Xeris Biopharma Holdings, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $17.5M, a 63.6% increase year-over-year.
  • Xeris Biopharma Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $10.7M, a 11.9% decline from 2022.
  • Xeris Biopharma Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $12.2M, a 6.85% increase from 2021.
  • Xeris Biopharma Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $11.4M, a 37.6% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $17.5M $6.77M +$4.31M +175% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-08
Q2 2024 $13.2M $4.23M +$1.31M +44.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $11.9M $3.77M +$1.2M +46.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $10.7M $2.77M +$1K +0.04% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 $10.7M $2.46M -$484K -16.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 $11.2M $2.93M -$224K -7.11% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $11.4M $2.56M -$737K -22.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $12.2M $2.77M +$23K +0.84% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 $12.1M $2.94M -$724K -19.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $12.9M $3.15M +$640K +25.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $12.2M $3.3M +$840K +34.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $11.4M $2.74M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 $3.67M +$1.61M +78.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $2.51M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $2.46M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q3 2020 $2.05M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.